PAN-CANCER PLATINUM RESPONSE PREDICTOR

Patent №

US 11,842,805

Granted

2023-12-12

Filed 2022

Owner

CARIS MPI, INC.

Lab

AI components

2

ml · planning

Assignment

Recorded

Dataset

AIPD

2023_r1 edition

Application

17831274

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that correlate with response of cancer patients to platinum-based chemotherapy. Described herein are data structures, data processing, and machine learning models to predict a probability of benefit of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising platinum therapy.

Machine learningPlanningC12Q 1/6886G16H 20/10G06N 3/084G06N 20/00G16B 20/40G16H 10/40G16H 10/60G16H 50/20+5 more

AI classification

Machine learning1.00
Planning0.89
Knowledge representation0.30
AI hardware0.23
Vision0.21
Natural language0.08
Evolutionary computation0.00
Speech0.00

Ownership

CARIS MPI, INC.

assignment · 646250146

Assignors

ABRAHAM, JIM, KORN, WOLFGANG MICHAEL, SPETZLER, DAVID

On an employer assignment, the assignors are typically the inventors.

© 2026 NYSGPT2525 LLC